Painful joint condition is treated with hormone produced during pregnancy

Painful joint condition is treated with hormone produced during pregnancy


Beginning in the first trimester of pregnancy, the body begins to produce the hormone relaxin, which loosens the expectant mother's muscles, joints and ligaments to help her body accommodate a growing baby and prepare for birth. When the researchers observed that patients with a common and painful joint condition called arthrofibrosis experienced long-lasting relief during and after pregnancy, they reached out to the colleagues in the lab to confirm his suspicion that relaxin could explain the phenomenon.

In a first-of-its-kind study, the researchers set to investigate whether relaxin's joint-loosening properties could be applied to alleviate symptoms of arthrofibrosis. The team found that multiple injections of human relaxin directly into the afflicted joint restored range of motion and improved tissue health in an animal model of frozen shoulder, a painful and debilitating form of arthrofibrosis particularly common among middle aged, often diabetic women. The findings are published in the journal Proceedings of the National Academies of Sciences.

"Current treatment options for arthrofibrosis, such as physical therapy and medication provide only marginal or temporary relief and do not address the source of the pain and stiffness," said the senior author. "While more research is needed, repurposing this pregnancy hormone as a treatment for arthrofibrosis could provide an unprecedented opportunity."

Most common in the shoulders, knees, hips, wrists and ankles, arthrofibrosis affects more than five percent of the general population. Characterized by pain accompanied by a reduction in range of motion, arthrofibrosis is caused by an excessive build-up of scar tissue in the joint, triggered by injury, trauma, long-term immobility, or surgery. Up to a third of patients who have undergone ACL reconstruction surgery can end up with arthrofibrosis.

In the new study, using human cells in vitro, researchers showed that a specific version of the hormone, human relaxin-2, inhibits cells' production of scar tissue and by indirectly downregulating production of collagen - the strong protein that supports joints and other tissues throughout the body, but is overproduced in scarring. Next they showed in an animal model of frozen shoulder that multiple injections to the joint resulted in significant and lasting improvements in range of motion, while a single injection to the joint, or systemic treatment did not. Similarly, when the scientists looked at the joint tissues, the animals that received multiple injections of relaxin to the joint appeared to undergo changes indicating restorative healing.

More studies will be necessary before investigating relaxin's efficacy for treatment of arthrofibrosis in humans, but the team is optimistic that the naturally-occurring and well-tolerated hormone could offer relief for millions of people.

"Arthrofibrosis is a widespread disease, occurring in all joints, and its high incidence, limited treatment options and poor patient outcomes call for alternative and effective non-surgical solutions," said another author. "The local delivery of relaxin-2 offers a potential paradigm shift in the treatment for the millions of individuals who are affected by arthrofibrosis every year."

https://www.bidmc.org/about-bidmc/news/2019/06/relaxin-alleviates-symptoms-of-arthrofibrosis

https://www.pnas.org/content/early/2019/05/29/1900355116

Edited

Rating

Unrated